Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BO-653 for Prevention of Post-Angioplasty Restenosis
NCT00055510Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of BO-653 in coronary restenosis (4 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Prevention of restenosis at 6 months. Status: completed.
02
Drugs
BO-653
03
Conditions
coronary restenosis
Beyond the preview
Go deeper on NCT00055510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055510.